AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27405587 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Anxiety Treatment in Schools (CATS)
Number of subjects: 360
Study 27405587 — intervention group
Group type: COMPARATOR
Intervention: FRIENDS protocol
Number of subjects: 360
Study 27405587 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies (train-the-trainer vs. train-the-trainer + ongoing consultation)
Number of subjects: 360
Study 25370953 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of acotiamide
Number of subjects: 12
Study 25370953 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of acotiamide
Number of subjects: 12
Study 25370953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 22176212 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual aid (AVA)
Number of subjects: 120
Study 22176212 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AVA)
Number of subjects: 120
Study 22176212 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 120
Study 20483046 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg subcutaneously twice weekly
Number of subjects: 84
Study 17563154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (CBT)
Number of subjects: 91
Study 17563154 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 91
Study 17563154 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT plus imipramine
Number of subjects: 91
Study 17563154 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT plus placebo
Number of subjects: 91
Study 16095473 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic listening training
Number of subjects: 57
Study 16095473 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 57
Study 11881883 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at fresh gas flows of 3, 1, and 0.5 litre min(‐1)
Number of subjects: 302
Study 11881883 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane at fresh gas flows of 3, 1, and 0.5 litre min(‐1)
Number of subjects: 302
Study 11881883 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane and enflurane at fresh gas flows of 0.5 and 3 litre min(‐1)
Number of subjects: 302
Study 11881883 — intervention group
Group type: EXPERIMENTAL
Intervention: More soluble agents (Isoflurane, enflurane)
Number of subjects: 302
Study 11881883 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 302
Study 10207805 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics plus albumin, 12.5 g/day (group B)
Number of subjects: 126
Study 10207805 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics plus albumin (25 g/week) (group B)
Number of subjects: 126
Study 10207805 — intervention group
Group type: COMPARATOR
Intervention: Diuretics (group A)
Number of subjects: 126
Study 7705006 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (10 pmol min-1 kg-1)
Number of subjects: 8
Study 7705006 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide (10 pmol min-1 kg-1)
Number of subjects: 8
Study 7705006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2650896 — intervention group
Group type: COMPARATOR
Intervention: Group I: 20 ml of lidocaine two per cent with epinephrine via needle at a rate of 5 ml.30 sec‐1 after a 3 ml test dose
Number of subjects: 45
Study 2650896 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II: 20 ml of lidocaine two per cent with epinephrine in increments of 5 ml injected through a catheter after a 3 ml test dose
Number of subjects: 45
Study 2650896 — intervention group
Group type: COMPARATOR
Intervention: Group I
Number of subjects: 45
Study 2650896 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II
Number of subjects: 45
Study 2650896 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study 971703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin (0.5, 1, and 2 g)
Number of subjects: 18
Study 971703 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin (0.5, 1, and 2 g)
Number of subjects: 18
Study 31543474 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg daily for one week, then 100 mg daily for up to 11 weeks
Number of subjects: 655
Study 31543474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 655
Study 31543474 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 655
Study 26031901 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton treatment
Number of subjects: 526
Study 26031901 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast treatment
Number of subjects: 526
Study 24908956 — intervention group
Group type: EXPERIMENTAL
Intervention: Vazonat (1000 mg/day intravenously for 15 days, then 250 mg 3 times per os for 1 month)
Number of subjects: 92
Study 24908956 — intervention group
Group type: EXPERIMENTAL
Intervention: Vazonat (1000 mg/day intravenously for 15 days, then 250 mg 3 times per os for 1 month) + Adapto (500 mg twice a day throughout the supervision period)
Number of subjects: 92
Study 24908956 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy (control group)
Number of subjects: 92
Study 23749780 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise programme with motivational techniques
Number of subjects: 143
Study 23749780 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 143
Study 20217115 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose ingestion (75 g of glucose 1 hour before exercise)
Number of subjects: 15
Study 20217115 — intervention group
Group type: COMPARATOR
Intervention: Control (fasting, n = 7)
Number of subjects: 15
Study 18387391 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA)
Number of subjects: 37
Study 18387391 — intervention group
Group type: COMPARATOR
Intervention: Pentosan polysulfate sodium (PPS)
Number of subjects: 37
Study 16572114 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 16572114 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline albuminuria
Number of subjects: 0
Study 14985796 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Slot light curing (Reliance Ortho 2000 curing light with Power slot), curing every bracket for 6 seconds
Number of subjects: 50
Study 14985796 — intervention group
Group type: COMPARATOR
Intervention: Conventional light curing (Kulzer light curing machine), curing every bracket for 20 seconds using Quick Cure Composite resin (Reliance Orthodontics)
Number of subjects: 50
Study 10902827 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin sodium (40 mg daily)
Number of subjects: 16
Study 8737216 — intervention group
Group type: EXPERIMENTAL
Intervention: L-propionylcarnitine (1500 mg daily for 6 weeks)
Number of subjects: 46
Study 8737216 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (180 mg daily for 3 weeks, followed by 360 mg daily for 3 weeks)
Number of subjects: 46
Study 7840730 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol (100 mg/day)
Number of subjects: 39
Study 7840730 — intervention group
Group type: EXPERIMENTAL
Intervention: nicardipine (90 mg/day)
Number of subjects: 39
Study 7840730 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril (75 mg/day)
Number of subjects: 39
Study 7840730 — intervention group
Group type: COMPARATOR
Intervention: chlorthalidone (control group)
Number of subjects: 39
Study 2900977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening at 15 weeks
Number of subjects: 2482
Study 2900977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening at 15 weeks (for babies born to screened women who smoked)
Number of subjects: 2482
Study 2900977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening at 15 weeks (for babies born to non-smokers)
Number of subjects: 2482
Study 31161855 — intervention group
Group type: EXPERIMENTAL
Intervention: Isostretching twice a week for 45 days
Number of subjects: 54
Study 31161855 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list for physical therapy)
Number of subjects: 54
Study 31596326 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling (FMS) with systemic azithromycin (500 mg/day for three consecutive days)
Number of subjects: 34
Study 31596326 — intervention group
Group type: COMPARATOR
Intervention: Quadrant-wise scaling and root planning (QSRP) with systemic azithromycin (500 mg/day for three consecutive days)
Number of subjects: 34
Study 28249084 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3602
Study 28249084 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus GPI
Number of subjects: 3602
Study 28719693 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/d of vitamin D oral supplementation (high-dose group)
Number of subjects: 703
Study 28719693 — intervention group
Group type: COMPARATOR
Intervention: 400 IU/d of vitamin D oral supplementation (standard-dose group)
Number of subjects: 703
Study 23746666 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab combined with cisplatin and fluorouracil
Number of subjects: 657
Study 23746666 — intervention group
Group type: COMPARATOR
Intervention: Control group (cisplatin and fluorouracil only)
Number of subjects: 657
Study 22119973 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum CA-125 levels
Number of subjects: 30
Study 22119973 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis
Number of subjects: 30
Study 19562534 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 45
Study 19562534 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia + Epidural (GA+E)
Number of subjects: 45
Study 19562534 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia + Lumbar Plexus Block (GA+LPB)
Number of subjects: 45
Study 17553362 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass, selective or opportunistic screening for prostate cancer
Number of subjects: 0
Study 17553362 — intervention group
Group type: COMPARATOR
Intervention: No screening
Number of subjects: 0
Study 15271714 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (n = 6)
Number of subjects: 10
Study 15271714 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (n = 4)
Number of subjects: 10
Study 15271714 — intervention group
Group type: COMPARATOR
Intervention: Both Propofol and Thiopental
Number of subjects: 10
Study 11338290 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino-acid-based formula (AA)
Number of subjects: 73
Study 11338290 — intervention group
Group type: COMPARATOR
Intervention: Extensively hydrolyzed cow's milk formula (eHF)
Number of subjects: 73
Study 8780279 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled intranasal analgesia (PCINA)
Number of subjects: 50
Study 8780279 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (IV PCA)
Number of subjects: 50
Study 1502842 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent influenza virus vaccine containing B/Yamagata/16/88
Number of subjects: 104
Study 1502842 — intervention group
Group type: EXPERIMENTAL
Intervention: Madin‐Darby canine kidney (MDCK)‐grown virus as an antigen in the haemagglutination inhibition test (HI)
Number of subjects: 104
Study 6429878 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine (0.5 mg)
Number of subjects: 0
Study 6429878 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Cromoglycate (20 mg)
Number of subjects: 0
Study 6429878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (0.5 mg)
Number of subjects: 0
Study 6429878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31299392 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using 5% 5-aminolevulinic acid in gel form, irradiated with a halogen lamp (590-760 nm) for 10 minutes, repeated weekly for 10 weeks.
Number of subjects: 10
Study 27013028 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 28
Study 27013028 — intervention group
Group type: COMPARATOR
Intervention: Standard Multimodal Therapy (TRAD)
Number of subjects: 28
Study 25809913 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with probiotics (Bacillus subtilis and Streptococcus faecium) and mosapride (various doses)
Number of subjects: 285
Study 25809913 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with probiotics and mosapride
Number of subjects: 285
Study 25809913 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with probiotics and mosapride (group 4)
Number of subjects: 285
Study 25809913 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with probiotics (group 1)
Number of subjects: 285
Study 25809913 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with probiotics (group 4)
Number of subjects: 285
Study 25809913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 23599248 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent infusion (every 4 hours from 8:00 to 20:00)
Number of subjects: 34
Study 23599248 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion (24 hours/d)
Number of subjects: 34
Study 22581391 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (400 μg/kg body weight) with alcohol
Number of subjects: 20
Study 22581391 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (doses aimed at 0.5 and 0.7 mg/mL) with THC
Number of subjects: 20
Study 22581391 — intervention group
Group type: EXPERIMENTAL
Intervention: Dräger Drug Test® 5000
Number of subjects: 20
Study 22581391 — intervention group
Group type: EXPERIMENTAL
Intervention: Securetec Drugwipe® 5
Number of subjects: 20
Study 20043432 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum breastfeeding counselling (peer breastfeeding counselling)
Number of subjects: 179
Study 20043432 — intervention group
Group type: COMPARATOR
Intervention: No counselling (control group)
Number of subjects: 179
Study 17695680 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged antibiotic therapy
Number of subjects: 0
Study 17695680 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 17695680 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of prolonged antibiotic therapy and surgery
Number of subjects: 0
Study 15477122 — intervention group
Group type: EXPERIMENTAL
Intervention: Sivelestat sodium hydrate (Sivelestat)
Number of subjects: 250
Study 15477122 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 250
Study 11473855 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 microg/kg IV
Number of subjects: 40
Study 11473855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9739379 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (1.2 Gy bid, total dose 74.4 Gy) and simultaneous CDDP chemotherapy (20 mg/m2 daily, 5 days in week 1 and 5)
Number of subjects: 64
Study 9739379 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy and simultaneous CDDP chemotherapy
Number of subjects: 64
Study 9425393 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (1 microgram/kg)
Number of subjects: 12
Study 9425393 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin plus GHRH‐(1‐29)‐NH2
Number of subjects: 12
Study 9425393 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (0.5 microgram/kg)
Number of subjects: 12
Study 9425393 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH‐(1‐29)‐NH2 (0.5 microgram/kg)
Number of subjects: 12
Study 9425393 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of SS20 infusion
Number of subjects: 12
Study 2523322 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg NET injectable microspheres
Number of subjects: 131
Study 2523322 — intervention group
Group type: COMPARATOR
Intervention: 65 mg NET injectable microspheres
Number of subjects: 131
Study 2523322 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses (65 mg and 100 mg)
Number of subjects: 131
Study 333492 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 23
Study 333492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30614767 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine tube bundles (FTBs)
Number of subjects: 60
Study 30614767 — intervention group
Group type: COMPARATOR
Intervention: Traditional drainage tube
Number of subjects: 60
Study 29266892 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual psychoprophylaxis (video watched before admission)
Number of subjects: 100
Study 29266892 — intervention group
Group type: COMPARATOR
Intervention: Control group (no audiovisual psychoprophylaxis)
Number of subjects: 100
Study 26212230 — intervention group
Group type: EXPERIMENTAL
Intervention: Home set-up for unattended home-based polysomnography (H-PSG)
Number of subjects: 102
Study 26212230 — intervention group
Group type: COMPARATOR
Intervention: Sleep laboratory set-up for unattended home-based polysomnography (H-PSG)
Number of subjects: 102
Study 23790553 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-thin wall pen needles (XTW PNs)
Number of subjects: 216
Study 23790553 — intervention group
Group type: COMPARATOR
Intervention: Current pen needles (usual PNs)
Number of subjects: 216
Study 21808759 — intervention group
Group type: EXPERIMENTAL
Intervention: VN membrane (new cross-linked collagen membrane)
Number of subjects: 16
Study 21808759 — intervention group
Group type: COMPARATOR
Intervention: BG membrane (native collagen membrane)
Number of subjects: 16
Study 21808759 — intervention group
Group type: EXPERIMENTAL
Intervention: VN membrane
Number of subjects: 16
Study 21808759 — intervention group
Group type: COMPARATOR
Intervention: BG membrane
Number of subjects: 16
Study 19596188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 microg once daily via metered-dose inhaler (CIC160)
Number of subjects: 0
Study 19596188 — intervention group
Group type: COMPARATOR
Intervention: Ciclesonide 160 microg once daily via AeroChamber Plus (CIC160P)
Number of subjects: 0
Study 19596188 — intervention group
Group type: COMPARATOR
Intervention: Ciclesonide 160 microg once daily via AeroChamber MAX (CIC160M)
Number of subjects: 0
Study 16458625 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded medical treatment
Number of subjects: 100
Study 16458625 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 100
Study 15080829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with Dermatophagoides pteronyssinus and D. farinae 50/50 allergen extract for 2 years
Number of subjects: 32
Study 15080829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11418492 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric taste stimuli applied to the right side of the tongue
Number of subjects: 11
Study 11418492 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric taste stimuli applied to the left side of the tongue
Number of subjects: 11
Study 11418492 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric taste stimuli
Number of subjects: 11
Study 9241097 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin at 30 pmol min(‐1)
Number of subjects: 16
Study 9241097 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP at 30 pmol min(‐1)
Number of subjects: 16
Study 9241097 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin at 10 pmol min(‐1)
Number of subjects: 16
Study 9241097 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP at 10 pmol min(‐1)
Number of subjects: 16
Study 8032063 — intervention group
Group type: EXPERIMENTAL
Intervention: HT-LVH
Number of subjects: 126
Study 8032063 — intervention group
Group type: EXPERIMENTAL
Intervention: HT-LVH with ST segment depression
Number of subjects: 126
Study 8032063 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG-LVH in terms of voltage
Number of subjects: 126
Study 8032063 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cholesterol levels
Number of subjects: 126
Study 3108045 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination clomiphene/hMG
Number of subjects: 126
Study 3108045 — intervention group
Group type: COMPARATOR
Intervention: hMG alone
Number of subjects: 126
Study 3108045 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic punctures
Number of subjects: 126
Study 3108045 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonically guided punctures
Number of subjects: 126
Study 3108045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonically guided punctures with clomiphene/hMG
Number of subjects: 126
Study 3108045 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonically guided punctures with hMG alone
Number of subjects: 126
Study 30377402 — intervention group
Group type: EXPERIMENTAL
Intervention: Injected with levobupivacaine
Number of subjects: 294
Study 30377402 — intervention group
Group type: COMPARATOR
Intervention: Injected with saline (Control)
Number of subjects: 294
Study 26604272 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic amoxicillin and metronidazole during the first, nonsurgical phase of periodontal therapy (phase 1)
Number of subjects: 80
Study 26604272 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive antibiotics during the first phase
Number of subjects: 80
Study 26604272 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving antibiotics during the second, surgical phase (phase 2)
Number of subjects: 80
Study 26604272 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive antibiotics during the second phase
Number of subjects: 80
Study 25808531 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported knee instability group
Number of subjects: 53
Study 22454003 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible(MIB) regimen (24-120 days' active hormonal intake with 4-day tablet-free intervals)
Number of subjects: 1067
Study 22454003 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimen (24 days' active hormonal intake followed by a 4-day hormone-free interval)
Number of subjects: 1067